Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Active, not recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10535
Shown on this page
12
Current sort
Recently updated
Status scope
Active, not recruiting
Additional filters apply within this recruitment status.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this status page

These controls apply only within Active, not recruiting. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 1357–1368 of 10,535 matching trials with status Active, not recruiting.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional

Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy

NCT05591118
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Anticoagulant Therapy, Catheter-Directed Therapy
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
40
States / cities
Birmingham, Alabama • Palo Alto, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 14, 2026, 8:25 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

NCT04989803
View directory record Official record
Conditions
Relapsed and/or Refractory B-cell Lymphoma
Interventions
Cyclophosphamide, Fludarabine, KITE-363, KITE-753
Drug · Biological
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
21
States / cities
Gilbert, Arizona • Duarte, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 14, 2026, 8:25 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

NCT03075696
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Glofitamab, Obinutuzumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
6
States / cities
Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 14, 2026, 8:25 PM EST
Active, not recruiting Phase 2 Interventional

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

NCT06617923
View directory record Official record
Conditions
Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Interventions
Senaparib, Temozolomide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 14, 2026, 8:25 PM EST
Active, not recruiting No phase listed Observational

Pyruvate Kinase Deficiency Global Longitudinal Registry

NCT03481738
View directory record Official record
Conditions
Pyruvate Kinase Deficiency
Interventions
Not listed
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 14, 2026, 8:25 PM EST
Active, not recruiting Early Phase 1 Interventional

Daily Aspirin Treatment After Preeclampsia

NCT06168461
View directory record Official record
Conditions
Preeclampsia
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 14, 2026, 8:25 PM EST
Active, not recruiting Not applicable Interventional

Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction

NCT05839730
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
Interventions
Pacemaker PLR + TRT ON, Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Naples, Florida • O'Fallon, Illinois • Springfield, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 14, 2026, 8:25 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Suubi4PrEP: Improving PrEP Access and Adherence Among Adolescent Girls and Young Women in Uganda

NCT07002866
View directory record Official record
Conditions
HIV Prevention
Interventions
HIV Risk Reduction (HIVRR), PrEP Peer Supporters (PS), Matched Savings Accounts + Financial Literacy (FL)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
15 Years to 24 Years · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 14, 2026, 8:25 PM EST
Active, not recruiting Phase 1 Interventional

CART22 Alone or in Combination With huCART19 for ALL

NCT03620058
View directory record Official record
Conditions
Chemotherapy Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
CART22-65s cells, huCART19 Cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 14, 2026, 8:25 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period

NCT05144256
View directory record Official record
Conditions
Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Interventions
Mitapivat, Mitapivat-matching placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 14, 2026, 8:25 PM EST
Active, not recruiting Phase 2 Interventional

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

NCT06924970
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Tebapivat, Tebapivat Matched Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
16 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Farmington, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 14, 2026, 8:25 PM EST
Active, not recruiting Phase 1 Interventional Results available

Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma

NCT04658147
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab, Relatlimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Baltimore, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 14, 2026, 8:25 PM EST